Oleg Sofrygin

Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review

A role of PIEZO1 in iron metabolism in mice and humans

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Sickle-cell disease

Disorders of iron metabolism. Part II: iron deficiency and iron overload

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

A Review on Iron Chelators in Treatment of Iron Overload Syndromes.

International consensus statement on the peri‐operative management of anaemia and iron deficiency

Online social media fatigue and psychological wellbeing—A study of compulsive use, fear of missing out, fatigue, anxiety and depression

Sickle cell disease and stroke

Iron overload in thalassemia: different organs at different rates

Industry sponsorship and research outcome

Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.